Empowered Funds LLC bought a new position in Natera, Inc. (NASDAQ:NTRA – Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 18,541 shares of the medical research company’s stock, valued at approximately $5,033,000.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the company. United Capital Financial Advisors LLC acquired a new stake in shares of Natera during the 2nd quarter valued at about $1,099,000. Coastal Bridge Advisors LLC acquired a new position in Natera in the second quarter worth approximately $200,000. Jefferies Financial Group Inc. bought a new position in Natera during the second quarter valued at approximately $1,481,000. Public Employees Retirement System of Ohio bought a new position in Natera during the second quarter valued at approximately $10,579,000. Finally, Capstone Investment Advisors LLC acquired a new stake in Natera in the second quarter valued at approximately $374,000. 99.90% of the stock is owned by hedge funds and other institutional investors.
Insiders Place Their Bets
In related news, Director Herm Rosenman sold 16,530 shares of the business’s stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $250.00, for a total transaction of $4,132,500.00. Following the completion of the transaction, the director owned 4,250 shares of the company’s stock, valued at approximately $1,062,500. The trade was a 79.55% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gail Boxer Marcus sold 11,000 shares of the business’s stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $217.21, for a total value of $2,389,310.00. Following the transaction, the director directly owned 6,183 shares of the company’s stock, valued at $1,343,009.43. This represents a 64.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 103,472 shares of company stock valued at $24,960,134 in the last ninety days. Company insiders own 5.05% of the company’s stock.
Natera Trading Down 1.3%
Natera (NASDAQ:NTRA – Get Free Report) last released its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.02. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm had revenue of $752.75 million during the quarter, compared to analyst estimates of $661.24 million. During the same quarter in the previous year, the business earned ($0.74) EPS. The business’s revenue was up 37.7% on a year-over-year basis. As a group, analysts anticipate that Natera, Inc. will post -1.02 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research firms have commented on NTRA. Zacks Research raised shares of Natera from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 12th. Citigroup raised their price target on shares of Natera from $315.00 to $365.00 and gave the company a “buy” rating in a report on Thursday, August 13th. Wells Fargo & Company lifted their price objective on shares of Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a research note on Friday, August 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Natera in a report on Friday, July 17th. Finally, Guggenheim increased their target price on shares of Natera from $290.00 to $360.00 and gave the stock a “buy” rating in a research report on Wednesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $319.38.
Get Our Latest Research Report on Natera
Natera Profile
Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.
Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.
See Also
- Five stocks we like better than Natera
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRA – Free Report).
Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.
